Follow-up testing after colposcopy: Five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less

Journal of Lower Genital Tract Disease

Volumn 17, Issue 5 SUPPL.1, 2013, Pages

  Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Raine Bennett, Tina ^e   Gage, Julia C ^a   Kinney, Walter K ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Cervical intraepithelial neoplasia (CIN); Colposcopy; Human papillomavirus (HPV); Pap

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SCREENING; CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 1; CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE 2; COLPOSCOPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; UNITED STATES; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; COLPOSCOPY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

EID: 84876105258     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31828543b1     Document Type: Article

References (11)

1. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156: 880-91, W312.
2. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012;16: 175-204.
3. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007; 11: 223-39.
4. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12: 186-92.
5. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92(4 Pt 2): 727-35.
6. Cox JT, Schiffman M, Solomon D. Prospective followup suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003;188: 1406-12.
7. Pretorius RG, Peterson P, Azizi F, Burchette RJ. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less. Am J Obstet Gynecol 2006;195: 1260-5.
8. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013;17:S28YS35.
9. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114-9.
10. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN3+ and cervical cancer among women with HPV-positive and HPVnegative high-grade Pap results. J Low Genit Tract Dis 2013;17:S36YS42.
11. Walker JL, Wang SS, Schiffman M, Solomon D. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASC-US-LSILTriage Study (ALTS). Am J Obstet Gynecol 2006;195: 341-8.